April 5, 2013 / 6:16 AM / 4 years ago

AstraZeneca arthritis drug has mixed results in Phase III trial

1 Min Read

LONDON, April 5 (Reuters) - AstraZeneca's experimental rheumatoid arthritis pill fostamatinib produced mixed results in a late-stage clinical trial, the company said on Friday.

It achieved a statistically significant improvement in a test assessing signs and symptoms of the disease, but failed to show an improvement in an X-ray endpoint, according to results from the OSKIRA-1 Phase III study.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below